Chronic Obstructive Pulmonary Disease (COPD) represents a leading cause of morbidity globally. Recent advances in therapy aim to enhance patient outcomes. The combination of tiotropium bromide and olodaterol emerges as a promising strategy. These agents, each with distinct mechanisms, when used together, may potentiate therapeutic